{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:20Z","timestamp":1790223440469,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05820-0","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T10:17:01Z","timestamp":1752315421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy of prostate health index (PHI) in predicting pathological progression in low-risk localized prostate cancer cases under active surveillance protocol"],"prefix":"10.1007","volume":"43","author":[{"given":"Semih","family":"Aktas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"Y\u00fcceta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma","family":"Y\u00fcceta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin Aytac","family":"Ates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihat","family":"Genc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"1","key":"5820_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semradonc.2016.08.002","volume":"27","author":"TR Rebbeck","year":"2017","unstructured":"Rebbeck TR (2017) Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 27(1):3\u201310","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"5820_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3348\/kjr.2020.1224","volume":"22","author":"CH Lee","year":"2021","unstructured":"Lee CH, Tan TW, Tan CH (2021) Multiparametric MRI in active surveillance of prostate cancer: an overview and a practical approach. Korean J Radiol 22(7):1087\u20131099","journal-title":"Korean J Radiol"},{"issue":"3","key":"5820_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","volume":"4","author":"D Hettiarachchi","year":"2021","unstructured":"Hettiarachchi D, Lawrentschuk N, Lawrentschuk L et al (2021) Can serial multiparametric MRI during active surveillance avoid the need for prostate biopsies? Eur Urol Oncol 4(3):426\u2013436","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"5820_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrurol.2017.26","volume":"14","author":"SM Bruinsma","year":"2017","unstructured":"Bruinsma SM, Carroll PR, Carter HB et al (2017) Expert consensus document: semantics in active surveillance for localized prostate cancer. Nat Rev Urol 14(5):312\u2013322","journal-title":"Nat Rev Urol"},{"key":"5820_CR5","unstructured":"Beckman Coulter (2025) PHI Immunoassay. https:\/\/www.beckmancoulter.com. Accessed April"},{"issue":"2","key":"5820_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00432-013-1566-2","volume":"140","author":"H Hirama","year":"2014","unstructured":"Hirama H, Sugimoto M, Ito K et al (2014) Baseline [-2]proPSA-related indices predict pathological reclassification during active surveillance. J Cancer Res Clin Oncol 140(2):257\u2013263","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"5820_CR7","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1245\/s10434-016-5183-6","volume":"23","author":"PKF Chiu","year":"2016","unstructured":"Chiu PKF, Ng CF, Sem DS et al (2016) Prostate health index and %p2PSA predict aggressive prostate cancer pathology in Chinese patients. Ann Surg Oncol 23(8):2707\u20132714","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5820_CR8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2013.01.011","volume":"63","author":"M Lazzeri","year":"2013","unstructured":"Lazzeri M, Haese A, Abrate A et al (2013) Serum isoform [-2]proPSA derivatives improve prostate cancer prediction in the 2\u201310 ng\/ml PSA range. Eur Urol 63(6):986\u2013994","journal-title":"Eur Urol"},{"issue":"4","key":"5820_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00345-015-1643-z","volume":"34","author":"F Cantiello","year":"2016","unstructured":"Cantiello F, Russo GI, Cicione A et al (2016) PHI and PCA3 improve prognostic performance in active surveillance candidates. World J Urol 34(4):485\u2013493","journal-title":"World J Urol"},{"issue":"5","key":"5820_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","volume":"271","author":"JI Epstein","year":"1994","unstructured":"Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Predicting tumor extent in nonpalpable prostate cancer. JAMA 271(5):368\u2013374","journal-title":"JAMA"},{"issue":"16","key":"5820_CR11","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","volume":"267","author":"HB Carter","year":"1992","unstructured":"Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of PSA levels in men with and without prostate cancer. JAMA 267(16):2215\u20132220","journal-title":"JAMA"},{"issue":"1","key":"5820_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000442846","volume":"9","author":"C Ceylan","year":"2016","unstructured":"Ceylan C, Adayener C, Erdemir F et al (2016) Can the free\/total PSA ratio predict the Gleason score? Curr Urol 9(1):24\u201327","journal-title":"Curr Urol"},{"issue":"3","key":"5820_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/pcan.2017.3","volume":"20","author":"I Heidegger","year":"2017","unstructured":"Heidegger I, Tsaur I, Borgmann H et al (2017) ProPSA and PHI as markers for aggressiveness in low-risk prostate cancer. Prostate Cancer Prostatic Dis 20(3):271\u2013275","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"5820_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00345-019-02889-2","volume":"38","author":"PF Hsieh","year":"2020","unstructured":"Hsieh PF, Chang PL, Chen CL et al (2020) Combining PHI and MpMRI for diagnosis of clinically significant prostate cancer. World J Urol 38(5):1207\u20131214","journal-title":"World J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05820-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05820-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05820-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:04:06Z","timestamp":1767996246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05820-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5820"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05820-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approved by the Health Sciences University Istanbul Health Practice and Research Center, Clinical Research and Ethics Committee (16\/09\/2022\/Desicion Number: 287). All procedures involving human participants in this study adhered to the ethical standards of the 1964 Helsinki Declaration, as well as its subsequent amendments or similar ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}},{"value":"Informed consent was obtained from all participants involved in the research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"431"}}